Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Selective Mediastinal Lymph Node Sampling Versus Systematic medIastinal Lymph Node Dissection After Neoadjuvant Chemotherapy Combined With Immunotherapy for the Treatment of Clinical Stage IIA-IIIB (N2) Non-small Cell Lung Cancer

NCT07617389 is registered in ClinicalTrials.gov with Wen-zhao ZHONG as lead sponsor.

NCT NCT07617389
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07617389 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Selective Mediastinal Lymph Node Sampling Versus Systematic medIastinal Lymph Node Dissection After Neoadjuvant Chemotherapy Combined With Immunotherapy for the Treatment of Clinical Stage IIA-IIIB (N2) Non-small Cell Lung Cancer
Lead sponsor
Wen-zhao ZHONG
Phase
Phase 3
Overall status
Not yet recruiting
Start date
May 20, 2026
Completion date
June 1, 2030
Enrollment
358 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

selective mediastinal lymph node sampling, stage iia-iiib nsclc, systematic mediastinal lymph node dissection